CGTN
20.3.2021 13:19:10 CET | Business Wire | Press release
Chinese archaeologists announced on Saturday that some new major discoveries have been made at the legendary Sanxingdui Ruins site in southwest China, helping shed light on the cultural origins of the Chinese nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210320005008/en/
Archaeologists have found six new sacrificial pits and unearthed more than 500 items dating back about 3,000 years at the Sanxingdui Ruins in Sichuan Province, the National Cultural Heritage Administration (NCHA) announced in the provincial capital Chengdu.
Over 500 precious cultural relics discovered
Ranging from 3.5 to 19 square meters, these six sacrificial pits, which were discovered from November 2019 to May 2020, are in rectangular shape, according to NCHA. Among them, pits No.3, No.4, No.5 and No.6 have been excavated to the utensil layer so far, while pits No.7 and No.8 are being backfilled.
Together they form an area in which people of the ancient Shu civilization offered sacrifices to heaven, Earth and their ancestors, and prayed for prosperity and peace, according to Tang Fei, head of the excavation team at Sanxingdui and chief of the Sichuan Provincial Cultural Relics and Archaeology Research Institute.
The discoveries have shown the distinctiveness of the Shu civilization and the diversity of the Chinese civilization, said Ran Honglin, another researcher with the institute.
In addition, over 500 pieces of important cultural relics have been unearthed from these six pits, including the fragments of gold masks, bird-shaped gold ornaments, gold foil, painted bronze head portraits, giant bronze masks, bronze sacred tree, ivory, fragments of exquisite tooth carvings, jade cong and jade tools.
A gold mask has been unearthed at the No.5 sacrificial pit. With an area of about three square meters, it is the smallest pit, but it's where the most gold pieces were unearthed, according to archaeologists.
During the process, archaeologists have made full use of modern scientific and technological means to build an archaeological excavation cabin, integrated excavation platform and multi-functional excavation operation system.
With the support of professional teams of multiple disciplines and institutions, they have formed an integrated work mode combining traditional archaeology, laboratory archaeology, technological archaeology as well as the protection of cultural relics. The combination will ensure the high quality and high level of archaeological work, NCHA said at the conference.
Meanwhile, the NCHA has identified the "Research on the Civilization Process of Bashu in Sichuan-Chongqing Region" as a major program of the "Archaeological China" project, aiming to conduct in-depth study on the evolution of civilization in the region and its integration into the overall cultural landscape of the pluralistic unity of the Chinese nation.
Located in the city of Guanghan, some 40 kilometers from Sichuan's provincial capital Chengdu, the Sanxingdui Ruins site is regarded one of the most important archaeological discoveries in the 20th century. The excavation has lasted for nearly 100 years since the first discovery in the late 1920s.
In 1986, archaeologists found two large-scale sacrificial pits dating back to the Shang Dynasty (1600-1046 BC). Thousands of rare treasures were discovered from the two pits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210320005008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
